Synergy Spine Solutions closed a Series A equity financing of $30 million.
Proceeds will be used to complete enrollment of Synergy’s U.S. IDE 2-level clinical trial, continue patient follow-up on 1-level and 2-level clinical trials, Premarket Approval applications and continued ex-U.S. commercialization of the company’s cervical disc replacement.
The 2-Level trial will evaluate the safety and effectiveness of the Synergy Disc vs. anterior cervical discectomy and fusion for the treatment of degenerative disc disease in subjects that are symptomatic at two contiguous vertebral levels from C3 to C7. This multi-center, prospective, non-randomized, historically controlled study will be conducted on 200 patients at up to 25 sites.
Synergy Spine Solutions closed a Series A equity financing of $30 million.
Proceeds will be used to complete enrollment of Synergy’s U.S. IDE 2-level clinical trial, continue patient follow-up on 1-level and 2-level clinical trials, Premarket Approval applications and continued ex-U.S. commercialization of the company’s cervical disc...
Synergy Spine Solutions closed a Series A equity financing of $30 million.
Proceeds will be used to complete enrollment of Synergy’s U.S. IDE 2-level clinical trial, continue patient follow-up on 1-level and 2-level clinical trials, Premarket Approval applications and continued ex-U.S. commercialization of the company’s cervical disc replacement.
The 2-Level trial will evaluate the safety and effectiveness of the Synergy Disc vs. anterior cervical discectomy and fusion for the treatment of degenerative disc disease in subjects that are symptomatic at two contiguous vertebral levels from C3 to C7. This multi-center, prospective, non-randomized, historically controlled study will be conducted on 200 patients at up to 25 sites.
Copy to clipboard 
